X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Oragenics gain Odyssey’s assets including drug candidates, ONP-002 for treating mild traumatic brain injury, and for treating Niemann Pick Disease Type C, as well as Odyssey’s proprietary powder formulation and its nasal delivery device.
Lead Product(s): ONP-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ONP-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oragenics
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 02, 2024
Details:
ONP-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of moderate traumatic brain injury. It crosses BBB & activates gene response leading to the production of proteins that reduce inflammation, oxidative stress, and swelling.
Lead Product(s): ONP-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PRV-002
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Syneos Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 16, 2023
Details:
Through the agreement, Oragenics acquire Odyssey’s assets including drug candidates, ONP-002 for treating mild traumatic brain injury, and for treating Niemann Pick Disease Type C, as well as Odyssey’s proprietary powder formulation and its nasal delivery device.
Lead Product(s): ONP-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ONP-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oragenics
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 05, 2023
Details:
Oximes-based drug formulation is administered into the upper chamber of the nasal cavity using intranasal device. This helps antidote to cross the blood-brain barrier and spread throughout the brain quickly to reverse the harmful effects of the nerve gas.
Lead Product(s): Oximes-based Therapeutic
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
No severe adverse events were noted as PRV-002 was well-tolerated for all cohorts. No delays were instituted between cohorts. Vital signs, EKG readings, sleep patterns and breathing function were all normal through the entirety of the study.
Lead Product(s): PRV-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PRV-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avance Clinical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion), has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids.
Lead Product(s): PRV-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PRV-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids.
Lead Product(s): PRV-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PRV-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroid, also reduces behavioral pathology associated with brain injury symptoms.
Lead Product(s): PRV-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PRV-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion).In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids.
Lead Product(s): PRV-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PRV-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion), In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids.
Lead Product(s): PRV-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PRV-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
